S. Rueckinger

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

P. van Paassen, J. Horn, W. Wiersinga, 2020, The Lancet Rheumatology.

Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial

J. Horn, W. Wiersinga, N. Riedemann, 2020 .